PHARMAC publishes experts’ advice and seeks views on access criteria for COVID-19 treatments

PHARMAC

16 February 2022 - PHARMAC is releasing meeting records of its COVID-19 Treatments Advisory Group and seeking feedback on the patient access criteria for two COVID-19 anti-viral treatments – molnupiravir (Lagevrio) and nirmatrelvir and ritonavir (Paxlovid).

“To help us make decisions about COVID-19 treatments, we set up a COVID-19 Treatments Advisory Group,” says Dr David Hughes, Pharmac’s Chief Medical Officer. “They look at the evidence for these treatments, to help us understand how they could benefit New Zealanders.

Read PHARMAC press release

Michael Wonder

Posted by:

Michael Wonder